一分钟看懂
这是一项关于多发性骨髓瘤的III 期研究，登记的药物或干预包括JNJ-79635322；Teclistamab，当前状态为招募中。登记地点显示中国北京、长春、朝阳区、成都等城市有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
JNJ-79635322；Teclistamab · III 期
登记条件中文摘要
登记的基本范围为不限性别，年龄18 岁；另列出8项专业入选条件，需结合英文原文并由研究团队确认。
登记摘要未单独列出可展示的排除条件，请查看英文原文并向研究团队确认。
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- Peking Union Medical College Hospital · 北京
- Peking University First Hospital · 北京
- The First Hospital of Jilin University · 长春
- Beijing Chaoyang Hospital · 朝阳区
- Sichuan Academy of Medical Science Sichuan Provincial Peoples Hospital · 成都
- Sun Yat Sen University Cancer Center · 广州
- The First Affiliated Hospital Zhejiang University College of Medicine · 杭州
- The First Affiliated Hospital of NanChang University · 南昌
- Nanjing Drum Tower Hospital · 南京
- Shanghai Fourth People s Hospital · 上海
- Peking University Shenzhen Hospital · 深圳
- Tianjin Medical University Cancer Institute and Hospital · 天津
- Institute of Hematology and Blood Diseases Hospital Chinese Academy of Medical Sciences · Tijian
- The First Affiliated Hospital of Wenzhou Medical University · 温州
- Wuhan Tongji Hospital Tongji Medical College · 武汉
- The Second Affiliated Hospital of Xi'an Jiaotong University · 西安
公开的入选条件
- Inclusion criteria:
- * Documented diagnosis of multiple myeloma (MM) as defined by the criteria below: a. MM diagnosis according to the international myeloma working group (IMWG) diagnostic criteria, b. Measurable disease at screening as assessed by central laboratory
- * Received 1 to 3 prior lines of antimyeloma therapy, including an anti-cluster of differentiation (CD) 38 antibody and lenalidomide
- * Have an eastern cooperative oncology group (ECOG) performance status of 0 to 2 at screening and immediately before the first dose of study medication
- * Have clinical laboratory values meeting the criteria specified in the protocol during the screening and within 1 day of the start of administration of study treatment
- Exclusion criteria:
- * Major surgery, (for example, requiring general anesthesia) or significant traumatic injury within 2 weeks prior to first dose, or will not have fully recovered from surgery, or has surgery planned during the time the participant is expected to participate in
- * Suspected or known allergies, hypersensitivity, intolerance or other contraindications to the use of JNJ-79635322 or teclistamab or their excipients
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT07518186；登记信息更新于 2026-09-25。